Armata Pharma earnings beat by $0.17, revenue topped estimates

Armata Pharma (ARMP) reported Q3 EPS of -$0.24, beating estimates by $0.17, with revenue of $3.17M, exceeding expectations of $450K. The stock is down 18.42% over the last 3 months and 41.69% over the last 12 months. InvestingPro rates its financial health as 'fair performance'.

Original reporting
Published Nov 12, 2026, 11:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARMP
Bullish
medium confidence
Mentioned
$ARMP
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ARMPBullishMed
01

Why it matters

The earnings beat provides fresh data that could trigger short covering and modest buying, but the company's small size and recent price weakness limit the magnitude of any move.

02

Market read

Earnings surprise for a micro‑cap biotech; modest trading opportunity.

03

What to watch

Liquidity constraints and limited cash runway could dampen any upside from the earnings surprise.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Armata Pharma (NYSE: ARMP) is a micro‑cap biotech company with a history of volatile price moves and recent negative performance.

Company-level read

Ticker impact

$ARMPBullishMedium confidence
Context

Armata Pharma reported Q3 EPS of $-0.240, beating estimates by $0.17 and revenue of $3.17M versus $0.45M consensus.

Expected impact

potential modest upside as the beat could attract buyers despite recent downtrend

Evidence & confidence

The surprise earnings beat provides new information for a micro‑cap stock that has been declining, suggesting a short‑term rally.

Market effects

Limited impact on the broader biotech sector; micro‑cap earnings rarely move peers.

Primarily relevant to U.S. over‑the‑counter biotech investors.

Low

Counterpoint

The beat may be insufficient to reverse the long‑term downtrend; investors could remain skeptical.

Key entities

  • Armata Pharma

    Biotech firm reporting Q3 earnings.

Related articles

$ARMPMed

Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update ​ LOS ANGELES, Calif., November 12, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnolo

$ARMPMed

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3…

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus ba

$ARMPMedAI 8/10

ARMP Stock Draws Bullish Focus After New Phage Breakthrough

Armata Pharmaceuticals Inc. (ARMP) stock rose 11.52% on September 14, 2026, driven by positive sentiment and a new peer-reviewed study on its therapeutic bacteriophage Ar-KM. The company's AP-PA02 therapy has completed Phase 2 trials, and the study provides mechanistic insights, reducing perceived development risk. Despite negative profitability and low revenue, traders are focused on the company's catalysts and momentum.